This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2002;287:1518.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Patients with myocardial infarction (MI) characterized by ST-segment elevation who are treated with the blood thinner enoxaparin, a low-molecular-weight heparin, plus a clot dissolver are significantly less likely to die or have a repeat MI within 30 days than patients receiving unfractionated heparin, say Harvard Medical School investigators.

The findings appear in the March 5 issue of Circulation: Journal of the American Heart Association. Elliott Antman, MD, an author of the report and associate professor of medicine at Harvard, called for a larger clinical trial to determine whether enoxaparin should be standard treatment for severe MI. Enoxaparin has been shown to be superior to unfractionated heparin for patients with milder MI (without ST-segment elevation).

The study, ENTIRE-TIMI 23, involved 483 patients who presented with severe MI at hospitals in the United States and Europe. Participants were randomly assigned to standard reperfusion with a full dose of clot-dissolving . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?